Market Overview

Ariad Pharnaceuticals Continues To Rally

Share:
Related ARIA
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors
Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial

Following a BMO Capital upgrade to Outperform and price target raised to $14, Ariad Pharmaceuticals (NASDAQ: ARIA) shares are 20% percent higher in Friday's trading at 9.24. Earlier in the session, the issue traded as high as 9.83. That is the highest level for ARIA since it cascaded from 17.14 on October 8, 2013.

Posted-In: Technicals Movers & Shakers Intraday Update Trading Ideas General

 

Related Articles (ARIA)

Get Benzinga's Newsletters